Seth Lee
Patent Agent
Dr. Seth Lee is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and intellectual property matters, primarily in the additive manufacturing, medical device, biotechnology, and life sciences industries.
Prior to joining the firm, Seth conducted doctoral research on developing biomaterials based on supramolecular chemistry and self-assembly under the supervision of Professor Samuel I. Stupp at Northwestern University. During his postdoctoral research in the laboratory of Professor Helen H. Blau at Stanford University, he studied muscle stem cell biology for muscle regeneration.
Experience
Dr. Seth Lee is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and intellectual property matters, primarily in the additive manufacturing, medical device, biotechnology, and life sciences industries.
Prior to joining the firm, Seth conducted doctoral research on developing biomaterials based on supramolecular chemistry and self-assembly under the supervision of Professor Samuel I. Stupp at Northwestern University. During his postdoctoral research in the laboratory of Professor Helen H. Blau at Stanford University, he studied muscle stem cell biology for muscle regeneration.
Education
- Postdoctoral Scholar, Stanford University, 2017
- Ph.D., Materials Science and Engineering, Northwestern University, 2015Samsung Scholarship Ph.D. Fellow
- B.S., Materials Science and Engineering, Cornell University, 2009
Admissions
- U.S. Patent and Trademark Office
Credentials
Education
- Postdoctoral Scholar, Stanford University, 2017
- Ph.D., Materials Science and Engineering, Northwestern University, 2015Samsung Scholarship Ph.D. Fellow
- B.S., Materials Science and Engineering, Cornell University, 2009
Admissions
- U.S. Patent and Trademark Office
Select Publications
- Co-author with T. Fyrner, S. Stupp et al., "Sulfated glycopeptide nanostructures for multipotent protein activation," 12(8) Nature Nanotechnology 821-9, 2017
- Co-author with R. Freeman, N. Stephanopoulos, and S. Stupp et al., "Instructing cells with programmable peptide DNA hybrids," 8(15982) Nature Communications, 2017
- Co-author with R. Da Silva, E. Meijer, and S. Stupp et al., "Super-resolution microscopy reveals structural diversity in molecular exchange among peptide amphiphile nanofibers," 7(11561) Nature Communications, 2016
- Co-author with E. Pazos, S. Stupp et al., "Nucleation and growth of ordered arrays of silver nanoparticles on peptide nanofibers: hybrid nanostructures with antimicrobial properties," 138(17) Journal of the American Chemical Society 5507-10, 2016
- Co-author with C. Newcomb, M. Snead, and S. Stupp et al., "Supramolecular nanofibers enhance growth factor signaling by increasing lipid raft mobility," 16(5) Nano Letters 3042-50, 2016
- Co-author with E. Hsu, S. Stock, and S. Stupp et al., "Gel scaffolds of BMP-2-binding peptide amphiphile nanofibers for spinal arthrodesis," 4(1) Advanced Healthcare Materials 131-41, 2015
- Co-author with M. Conda-Sheridan, A. Preslar, and S. Stupp, "Esterase-activated release of naproxen from supramolecular nanofibers," 50(89) Chemical Communications, 2014
- Co-author with B. Huang, S. Stupp et al., "Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds," 34(2) Biomaterials 452-9, 2013
- Co-author with Y. Lim, G. Malliaras et al., "Spray-deposited poly(3,4-ethylenedioxythiophene): poly(styrenesulfonate) top electrode for organic solar cells," 93(19) Applied Physics Letters, 2008
Insights
Select Publications
- Co-author with T. Fyrner, S. Stupp et al., "Sulfated glycopeptide nanostructures for multipotent protein activation," 12(8) Nature Nanotechnology 821-9, 2017
- Co-author with R. Freeman, N. Stephanopoulos, and S. Stupp et al., "Instructing cells with programmable peptide DNA hybrids," 8(15982) Nature Communications, 2017
- Co-author with R. Da Silva, E. Meijer, and S. Stupp et al., "Super-resolution microscopy reveals structural diversity in molecular exchange among peptide amphiphile nanofibers," 7(11561) Nature Communications, 2016
- Co-author with E. Pazos, S. Stupp et al., "Nucleation and growth of ordered arrays of silver nanoparticles on peptide nanofibers: hybrid nanostructures with antimicrobial properties," 138(17) Journal of the American Chemical Society 5507-10, 2016
- Co-author with C. Newcomb, M. Snead, and S. Stupp et al., "Supramolecular nanofibers enhance growth factor signaling by increasing lipid raft mobility," 16(5) Nano Letters 3042-50, 2016
- Co-author with E. Hsu, S. Stock, and S. Stupp et al., "Gel scaffolds of BMP-2-binding peptide amphiphile nanofibers for spinal arthrodesis," 4(1) Advanced Healthcare Materials 131-41, 2015
- Co-author with M. Conda-Sheridan, A. Preslar, and S. Stupp, "Esterase-activated release of naproxen from supramolecular nanofibers," 50(89) Chemical Communications, 2014
- Co-author with B. Huang, S. Stupp et al., "Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds," 34(2) Biomaterials 452-9, 2013
- Co-author with Y. Lim, G. Malliaras et al., "Spray-deposited poly(3,4-ethylenedioxythiophene): poly(styrenesulfonate) top electrode for organic solar cells," 93(19) Applied Physics Letters, 2008
Recent Insights
Client Highlights
Wilson Sonsini Represents WuXi AppTec in Acquisition of OXGENE
On March 2, 2021, WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has completed its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Wilson Sonsini Goodrich & Rosati represented WuXi AppTec in the transaction, in collaboration with Taylor Wessing, which served as UK counsel.
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.